Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Trial Profile

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Censavudine (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions
  • Sponsors Transposon Therapeutics
  • Most Recent Events

    • 21 May 2024 According to an Transposon Therapeutics media release, the the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TPN-101 for progressive supranuclear palsy (PSP), supported by data from this study.
    • 13 Feb 2024 Results published in the Transposon Therapeutics Media Release
    • 14 Nov 2023 According to an Transposon Therapeutics media release, The predefined interim analysis was performed after all patients completed the 24-week double-blind portion of the study. The open-label extension of the study is ongoing.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top